It's hard to find a big name in health care that had a worse 2013 than Edwards Lifesciences (NYSE:EW). While the market's surged recently, Edwards's stock has plunged by more than 20%. Not only is this company facing sales of its innovative Sapien heart valve which look to fall below analyst expectations --it's also staring down competition that's eager to intrude on the U.S. market, where Edwards's Sapien currently is the only approved device of its type.
It's a desperate time for this hot name in medical devices, but is there a path for Edwards to rebound from its setbacks? The company this week won a big court case against competitor Medtronic (NYSE:MDT) over its rival's CoreValve device; Edwards is looking to keep its top opponent's device out of the U.S. market, which it's set to enter this year.
Is this too little, too late for Edwards, or can this stock mount a comeback? Find out in the video below, where Motley Fool contributor Dan Carroll takes you through all of the latest on Edwards Lifesciences's Sapien device -- and whether or not this innovative heart valve can spearhead a surprising surge in this struggling stock.